A shareholder lawsuit and Trump’s account of FBI involvement broaden the controversy, but neither establishes that espionage succeeded.
- By John K. Waters
- 11/10/2026
The board review and a congressional briefing request put the focus on security controls and leadership oversight, while key espionage claims remain unproven publicly.
- By John K. Waters
- 11/09/2026
Companies are deploying AI agents faster than they can monitor and control them effectively, according to a new report by Salt Security.
GPT-6 Cyber expands AI-assisted vulnerability research, but OpenAI’s own findings show why validation and human oversight remain necessary.
- By John K. Waters
- 11/05/2026
Democratic victories promise more scrutiny of AI companies and new pressure on the infrastructure behind them. For enterprise customers, the consequences could depend as much on where their suppliers build as on what Congress passes.
- By John K. Waters
- 11/05/2026
- By John K. Waters
- 11/04/2026
Enterprise AI spending is growing much faster than the number of businesses paying for it, according to new Menlo Ventures research that points to a shift from buying access for employees to financing work performed by agents.
- By John K. Waters
- 11/04/2026
Enterprises are deploying AI agents that can act within critical business applications, but security and governance controls are struggling to keep pace, according to new research from Delinea.
Anthropic’s IPO filing states that models have behaved differently when they recognize that they are being evaluated, limiting what safety tests can establish.
- By John K. Waters
- 10/28/2026
Anthropic is preparing to sell shares to public investors while preserving a governance structure intended to let it pursue AI safety decisions that could conflict with financial returns.
- By John K. Waters
- 10/28/2026
Anthropic’s proposed initial public offering is bringing a central question in the AI industry into sharper view: whether revenue from customers can support the computing capacity providers are committing to buy years in advance.
- By John K. Waters
- 10/28/2026
Among organizations using AI in critical business applications, 84% reported at least one AI-related issue in the past year, including incorrect financial transactions or actions that could not be traced or explained.
OpenAI has acquired biotechnology software startup Orchestra Bio, adding tools for coordinating drug-development programs to its Rosalind life sciences platform.
- By John K. Waters
- 10/25/2026